|Bid||235.10 x 243000|
|Ask||235.20 x 260500|
|Day's Range||233.70 - 235.40|
|52 Week Range||218.30 - 273.00|
|PE Ratio (TTM)||20.87|
|Earnings Date||Jan 26, 2016 - Feb 1, 2016|
|Forward Dividend & Yield||8.22 (3.22%)|
|1y Target Est||272.32|
Drugmakers plunged off a patent cliff earlier this decade, losing billions in sales as lucrative branded drugs lost exclusivity. An expensive lobbying effort aimed at preventing a repeat is paying off....
Roche Holding AG led European stocks lower after the Swiss pharmaceutical company unveiled data on the Aphinity breast-cancer study that disappointed analysts.
Roche’s breast cancer Perjeta decreased the risk of cancer returning in women whose tumors could be entirely removed using surgery, but the results were less impressive than what doctors hoped for--or what investors expected.
Roche Holding AG’s new breast cancer combination therapy barely outperformed a current gold-standard drug for the disease -- the company’s own decades-old Herceptin -- in its latest study.
Roche Holding AG is seeking a partner with experimental drugs that might help repair the damage caused to the nervous system by multiple sclerosis -- considered a key step in managing the debilitating ...
Human antibody discovery has come a long way in the last two decades, with contributions from transgenic mice and phage display. Author reviews the data on their success, speculates of why the former has outperformed, closing with thoughts on the future of antibody discovery